Drugs Giant AstraZeneca Reveals Higher Profits, Savings Plan
- On Thursday, October 29, 2026, Southside Bancshares Inc. reported third-quarter earnings of $28 million, a 4.2% linked-quarter increase driven by higher net interest income.
- Net interest margin expansion drove quarterly growth, rising 12 basis points to 3.0% from 2.9% in the second quarter due to improved loan and security yields.
- Diluted earnings per share reached $0.93, a 3.3% increase from the prior quarter, while the bank maintained a return on average tangible common equity of 16.3%.
- Moderating its 2026 loan growth guidance to low-to-mid single digits, Southside cited anticipated slowing in commercial real estate originations and $281 million in loan payoffs.
- The bank expects the September Federal Reserve rate increase to be accretive to yields, as approximately 55% of the loan book is scheduled to reprice over the next 90 days.
22 Articles
22 Articles
Drugs giant AstraZeneca reveals higher profits, savings plan
Profit after tax increased to $3.12 billion in the July-September period compared with the third quarter of last year thanks in large part to its cancer treatments, Britain's biggest drugs company said in a statement. Welcoming also a rise in revenue, chief executive Pascal Soriot said AstraZeneca had "multiple potential blockbuster" drugs in late-stage development. Its savings programme will cost $2.0 billion before delivering the desired yearl…
AstraZeneca launches $1.5 billion annual savings plan to invest in drug pipeline - Regional Media News
Oct 30 (Reuters) - AstraZeneca on Friday launched an unexpected restructuring drive aimed at investing in its new drug pipeline, hoping that annual savings of about $1.5 billion from the plan will keep the drugmaker on track to achieve its long-term ambitions. The Anglo-Swedish drugmaker [...]
AstraZeneca launches US$1.5bil annual savings plan to invest in drug pipeline
Drugmakers worldwide face growing scrutiny over their research pipelines, as valuations increasingly depend on successful late-stage trials rather than blockbuster drugs nearing patent expiry.
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
